3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer Pain
• Intervention / Treatment: Drug: 3D1002 (50 mg)(Phase IIa); Drug: 3D1002 (100 mg)(Phase IIa); Drug: 3D1002 (150 mg)(Phase IIa); Drug: 3D1002 monotherapy (Phase IIb); Drug: OxyContin monotherapy (Phase IIb); Drug: 3D1002 + OxyContin (Phase IIb)

Detailed Description

The investigational product in this study, 3D1002, is a selective antagonist of prostaglandin E2 receptor subtype 4 (EP4). The study is composed of two stages. Phase IIa stage is to assess the safety and efficacy of 3D1002 administered at doses of 50, 100 or 150 mg every 12 hour (q12h) for patients with moderate to severe cancer pain, and to determine the optimal recommended dose for further studies. Phase IIb stage is to evaluate the difference in the efficacy and safety of 3D1002 combined with OxyContin and OxyContin alone in treatment of patients with moderate to severe cancer pain.

• Study Type: Interventional
• Enrollment (Estimated): 177
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Qiling Huang; Phone Number: 18312677976; Email: qiling.huang@3d-medicines.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject must sign the informed consent in person prior to beginning any screening procedure.
2. Age ≥18, both male and female.
3. Subjects with a malignant tumor confirmed by histopathology or cytology.
4. Weight ≥40 kg at screening period.
5. Subjects have relatively stable cancer pain and require continuous analgesic medications (estimated treatment duration ≥2 weeks), as assessed by the investigator.
6. Estimated life expectancy ≥3 months.
7. Subjects are willing to not use any analgesic other than those specified in the study during the study treatment period.
8. ECOG PS score is 0-3.
9. Have adequate organ and bone marrow function.
10. The mean NRS scores per day during the washout period are ≥4.

Exclusion Criteria:

1. Known allergy to any of the active ingredients or excipients of the study drug, or have a history of allergy to other opioids or non-steroidal anti-inflammatory drugs (NSAIDs) and their related ingredients.
2. Have a persistent pain resulted from other medical conditions or unknown causes.
3. Subjects presenting with emergency symptoms such as intestinal obstruction/perforation, spinal cord compression, epidural metastasis, or fracture.
4. Subjects with known active/symptomatic central nervous system metastasis and/or cancerous meningitis.
5. Subjects plan to be treated with >10 mg/ day of prednisone or equivalent systemic corticosteroid during the study period.
6. Have a history of gastrointestinal bleeding or perforation.
7. Have a positive result of fecal occult blood test during screening period.
8. Have a history of serious cardiovascular diseases.
9. Have a history of an acute ischemic or hemorrhagic stroke within 6 months prior to screening.
10. Have a history of significant psychiatric disorders, such as schizophrenia and depression.
11. Subjects plan to receive radiotherapy, surgery, or a new regimen of systemic antitumor agents during the study treatment period (D1-D15).
12. Subjects have a history of alcohol abuse or drug abuse including opioids.
13. Subjects have significant opioid contraindications.
14. Pregnant or lactating women.
15. Subjects with other diseases that affect the oral administration or absorption of drugs.
16. Subjects are currently participating in another clinical study.
17. Other conditions deemed by the investigator to be inappropriate for participation in this study, such as poor compliance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3D1002 50 mg group (Phase IIa); 3D1002 is given 50 mg twice a day for 2 weeks.	Drug: 3D1002 (50 mg)(Phase IIa); 1 tablet of 3D1002 per oral dose
Experimental: 3D1002 100 mg group (Phase IIa); 3D1002 is given 100 mg twice a day for 2 weeks.	Drug: 3D1002 (100 mg)(Phase IIa); 2 tablets of 3D1002 per oral dose
Experimental: 3D1002 150 mg group (Phase IIa); 3D1002 is given 150 mg twice a day for 2 weeks.	Drug: 3D1002 (150 mg)(Phase IIa); 3 tablets of 3D1002 per oral dose
Experimental: 3D1002 monotherapy group (Phase IIb); 3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.	Drug: 3D1002 monotherapy (Phase IIb); 3D1002 is administered at recommended dose with mimic OxyContin tablets.
Experimental: OxyContin monotherapy group (Phase IIb); OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.	Drug: OxyContin monotherapy (Phase IIb); OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.
Experimental: 3D1002 + OxyContin group (Phase IIb); 3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.	Drug: 3D1002 + OxyContin (Phase IIb); 3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14)	①Average pain intensity is calculated daily for the past 24 hours using the NRS (0 = No pain, 10 = Worst pain imaginable). ②PID (pain intensity difference): Baseline pain intensity score (for the day prior to the day of randomization) minus pain intensity score at each given day.③SPID: the sum of the pain intensity difference generated daily from day 1 to the designated day.	1 to 14 days after receiving study treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects who achieve effective pain control	Effective pain control: mean NRS score within 0-3 points and episode of breakthrough pain ≤ 2 times in 24 hours	1 to 14 days after receiving study treatment
Time to achieve effective pain control		1 to 14 days after receiving study treatment
Time-specific pain intensity difference（PID）		1 to 14 days after receiving study treatment
Sum of pain intensity difference (SPID) in the NRS within 3,5 and 7 days post-treatment		from day 1 to 3, 5 and 7 after receiving study treatment, respectively
Time-specific subject self-rated pain relief based on Brief Pain Inventory Short Form (BPI-SF) Questionnaire Item 8	The pain relief is assessed daily for the past 24 hours based on the percentage of relief from baseline, ranging from 0 (no relief) to 100% (complete relief).	1 to 14 days after receiving study treatment
Sum of subject self-rated pain relief based on BPI-SF Questionnaire Item 8 within 3,5,7 and 14 days post-treatment		from day 1 to 3, 5, 7 and 14 after receiving study treatment, respectively
Proportion of subjects with pain response over 7 and 14 days after treatment	Pain response: at least 30% and 50% decrease in pain intensity NRS score from baseline.	1 to 14 days after receiving study treatment
Time to pain response		1 to 14 days after receiving study treatment
The number of breakthrough pain episodes and rescue dose of immediate-release oxycodone over 7 and 14 days after treatment;		1 to 14 days after receiving study treatment
Time-specific oxycodone dose, including immediate-release oxycodone capsules and sustained-release oxycodone tablets (the latter is only applicable for phaseⅡb)		1 to 14 days after receiving study treatment
Total dose of oxycodone over 3, 7, and 14 days post-treatment		1 to 14 days after receiving study treatment
Patient's global impression of change (PGI-C) over 7 and 14 days after treatment (for phase IIb only)	PGI-C is a participant rated instrument to measure participant's change in overall status of general condition including pain on a 7-point scale, with 1 being "very much improved" and 7 being "very much worse".	1 to 14 days after receiving study treatment
Frequency and severity of adverse events during treatment		1 to 14 days after receiving study treatment

Collaborators and Investigators

• Sponsor: 3D Medicines
• Investigators: Principal Investigator: Suxia Luo, Henan Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: January 24, 2022
• First Submitted That Met QC Criteria: February 22, 2022
• First Posted (Actual): March 3, 2022

Study Record Updates

• Last Update Posted (Actual): March 11, 2026
• Last Update Submitted That Met QC Criteria: March 9, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Cancer pain
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Cancer Pain; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Alkaloids; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds; Heterocyclic Compounds, 4 or More Rings; Morphinans; Opiate Alkaloids; Heterocyclic Compounds, Bridged-Ring; Phenanthrenes; Morphine Derivatives; Codeine; Oxycodone
• Other Study ID Numbers: 3D1002-CN-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No